Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Cancer patients taking regular medication for their pain often still have episodes of severe
pain that 'break through' despite their background pain treatment. Fentanyl is a strong,
short-acting pain killer often used to treat this 'breakthrough' pain. Nasalfent contains
fentanyl in a patented drug delivery system called PecSys and is given via a simple nasal
spray. This study will examine the long-term safety of Nasalfent in the treatment of
breakthrough cancer pain.